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Introduction {#sec005}
============

Components of thyroid hormone signaling are implicated in the development and progression, as well as in the prevention of various cancers including hepatocellular carcinoma (HCC) \[[@pone.0181878.ref001]--[@pone.0181878.ref003]\]. HCC usually develops in patients with liver cirrhosis \[[@pone.0181878.ref004], [@pone.0181878.ref005]\] and represents the second most common cause of cancer-related mortality in men globally \[[@pone.0181878.ref006]\].

The thyroid hormones (TH) tetraiodthyronine (T~4~) and, to a lesser extent, triiodthyronine (T~3~) are produced in the thyroid gland in a complex multi- step process, which is tightly controlled by the hypothalamus-pituitary-thyroid axis. Hypothalamic neurons produce the tripeptide thyrotropin-releasing-hormone (TRH), which uses the pituitary portal venous system to reach the anterior pituitary gland, where it binds to the TRH receptor in thyrotropic cells, and thereby stimulates both the production and pulsatile release of the glycoprotein thyrotropin (thyroid-stimulating hormone, TSH). By binding to the TSH-receptor situated at the basolateral membrane of thyrocytes, TSH activates thyroid hormone production and secretion.

The vast majority of both thyroid hormones is bound to the plasma proteins and therefore unable to bind to receptors in target tissues. This constellation allows preparation of a large pool of hormones, which can quickly be released when needed. Conversely, the smaller, unbound fraction of thyroid hormones is responsible for the actual physiological effects. The thyroid gland predominantly secretes T~4~, most of which is subjected to peripheral metabolism by deiodinase enzymes \[[@pone.0181878.ref007]\].

Since TH display extensive influence on regulatory mechanisms affecting the control of cellular growth and metabolism \[[@pone.0181878.ref007]--[@pone.0181878.ref010]\], there are myriad possible modes of interaction with both the development and progression of HCC. Although hypothyroidism has been shown to be associated with an elevated risk of HCC development \[[@pone.0181878.ref002], [@pone.0181878.ref011], [@pone.0181878.ref012]\], the role of TH in established HCC remains to be elucidated. Several preclinical studies have linked TH signaling to tumor-promoting actions, especially at advanced stages of hepatocarcinogenesis \[[@pone.0181878.ref013]--[@pone.0181878.ref015]\]. However, little is known about both the prevalence and clinical role of TH in patients with manifest HCC. Hence, we aimed to investigate the association of TH with clinical patient and tumor characteristics as well as their impact on the prognosis of HCC patients.

Materials and methods {#sec006}
=====================

Patient selection {#sec007}
-----------------

Data from all patients who were diagnosed with HCC by biopsy or radiological imaging according to the European Association for the Study of the Liver (EASL) \[[@pone.0181878.ref016]\] diagnostic criteria between August 1992 and February 2013 at the Medical University of Vienna were retrospectively collected and incorporated into a database. Patients who had received surgical treatment for HCC at any time after diagnosis were excluded from analysis. Only patients aged ≥18 years with TSH levels available at the time of diagnosis were eligible. Collection and retrospective analysis was approved by the Ethics Committee of the Medical University of Vienna.

Data acquisition {#sec008}
----------------

The date of HCC diagnosis (date of biopsy if available or diagnostic imaging) was considered the baseline of this study. Patient information was collected in a preexisting MS Access 2010 database (HCC database) in a pseudo-anonymous manner. Patient characteristics, laboratory parameters including thyroidal function (TSH, T3, T4, fT3, fT4), tumor characteristics, and parameters representing liver function were recorded from the patients' charts and from the electronic patients' information system. Determination of thyroid status was based on TSH and fT~4~ levels. We formed 5 subgroups: euthyreosis, hyperthyreosis (primary, secondary, and euthyroid hyperthyroxinemia), subclinical hyperthyreosis, subclinical hypothyreosis, hypothyreosis (primary and secondary), and thyroid hormone substitution. Liver function was assessed by MELD score and Child-Pugh score. The latter has been incorporated in the Barcelona Clinic Liver Cancer classification, the most widely used staging system for HCC, which has been endorsed by the American and European HCC guidelines \[[@pone.0181878.ref016], [@pone.0181878.ref017]\].

Statistics {#sec009}
----------

Baseline characteristics were summarized using descriptive statistics. Chi square test or Fisher's exact test were used to compare nominal data. Overall survival (OS) was defined as the time from date of diagnosis (date of biopsy if available or diagnostic imaging) until date of death or last contact. Survival curves were calculated using the Kaplan-Meier method and were compared by means of the log rank test (univariate analysis). Variables that reached a p-value of \<0.05 in univariate analysis were entered into a multivariate analysis. The multivariate analysis was performed using a Cox proportional hazard regression model. Statistical tests were two-sided and a p-value \<0.05 was considered significant. All statistical analyses were performed using SPSS version 17.0 (SPSS Inc., Chicago, IL).

Results {#sec010}
=======

Patient characteristics {#sec011}
-----------------------

Of 667 patients included ([Fig 1](#pone.0181878.g001){ref-type="fig"}), 82% of the patients were male, with a male to female ratio of 4.6:1. The median age at diagnosis was 64 years (range, 32--87 years). Six percent of all patients were on thyroid hormone substitution. Detailed patient characteristics are shown in [Table 1](#pone.0181878.t001){ref-type="table"}. Additional information on thyroid function is given in [S1 Table](#pone.0181878.s001){ref-type="supplementary-material"}. Mean follow-up was 65.5 months. Five hundred and forty-four (82%) patients died during the observation period.

![Flow chart of patient selection.\
Abbreviations: HCC, hepatocellular carcinoma; TSH, thyroid-stimulating hormone.](pone.0181878.g001){#pone.0181878.g001}

10.1371/journal.pone.0181878.t001

###### Patient characteristics.

![](pone.0181878.t001){#pone.0181878.t001g}

                                                                              N = 667      100%
  ----------------------------------------------------------------- --------- ------------ ------
  **Age (years)**                                                   Mean±SD   64±9.6       
  Range                                                             32--87                 
  **Sex**                                                           Male      547          82
  Female                                                            120       18           
  **Diabetes**                                                      NIDDM     152          23
  IDDM                                                              78        12           
  None                                                              437       66           
  **BMI (kg/m**^**2**^**)**[^1^](#t001fn002){ref-type="table-fn"}   Mean±SD   27±4.8       
  **Etiology**                                                      Alcohol   304          46
  HCV                                                               194       29           
  HBV                                                               52        8            
  NASH                                                              20        3            
  Cryptogenic                                                       65        10           
  other                                                             32        5            
  **Child-Pugh**                                                    A         286          43
  B                                                                 219       33           
  C                                                                 162       24           
  **MELD**                                                          Mean±SD   13±5.7       
  **ECOG PS**                                                       0         328          49
  ≥1                                                                339       51           
  **Largest tumor**                                                 ≤5cm      313          47
  \>5cm                                                             354       53           
  **Macrovascular Invasion**                                        No        489          73
  Yes                                                               178       27           
  **Extrahepatic metastases BCLC stage**                            No        577          87
  Yes                                                               90        14           
  A                                                                 90        14           
  B                                                                 143       21           
  C                                                                 268       40           
  D                                                                 166       25           
  **First line therapy**                                            PEI/RFA   138          21
  TACE                                                              180       27           
  Sorafenib                                                         63        9            
  BSC                                                               152       23           
  Other                                                             134       20           
  **CRP (mg/dl)**[^2^](#t001fn003){ref-type="table-fn"}             Mean±SD   2.62±3.59    
  **AFP (IU/ml)**[^3^](#t001fn004){ref-type="table-fn"}             Mean±SD   5982±25114   
  **TSH (uU/ml)**                                                   Mean±SD   2.2±2.3      
  **fT**~**4**~ **(ng/dl)**[^4^](#t001fn005){ref-type="table-fn"}   Mean±SD   1.3±0.3      
  **Thyroid hormone substitution**                                  Yes       41           6
  No                                                                626       94           

**Abbreviations**: AFP, α-fetoprotein; BCLC, Barcelona-Clinic Liver Cancer; BMI, body mass index; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT~4~, free tetraiodthyronine; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model of end-stage liver disease; NASH, non-alcoholic steatohepatitis; (N)IDDM, (non) insulin dependent diabetes mellitus; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TSH, thyroid-stimulating hormone.

^**1**^ missing, n = 23;

^**2**^ missing, n = 36;

^**3**^ missing, n = 9;

^**4**^ missing, n = 354

Association of thyroid-stimulating hormone (TSH) and free tetraiodthyronine (fT~4~) with patient, liver, and tumor characteristics {#sec012}
----------------------------------------------------------------------------------------------------------------------------------

TSH abnormalities significantly differed between age groups. While patients with low TSH concentrations were generally older (age \>65 vs. ≤65years, 68 vs. 32%) those with high TSH (\>3.77uU/ml) levels were predominantly younger (age \>65 vs. ≤65years, 39 vs. 61%; p = 0.007). Thyroid hormone substitution was more often observed in patients with low TSH (\<0.44uU/ml) concentration (24%) compared to those with normal (4%) or elevated TSH (13%) levels (p\<0.001). Finally, patients with high TSH concentrations had larger tumors (tumor \>5cm vs. ≤5cm, 61 vs. 39%) while the opposite was true for patients with low TSH concentrations (tumor \>5cm vs. ≤5cm, 32 vs. 68%; p = 0.005). No association was observed between other variables including e.g. Child-Pugh stage, metastasis, or macrovascular invasion ([Table 2](#pone.0181878.t002){ref-type="table"}). Notably, in patients with larger HCC (\>5cm), TSH levels were only significantly associated with sex and thyroid hormone substitution, but not with other variables that might correlate with larger HCC (i.e., etiology, Child-Pugh stage) ([S2 Table](#pone.0181878.s002){ref-type="supplementary-material"}).

10.1371/journal.pone.0181878.t002

###### Association between thyroid-stimulating hormone (TSH) and patient, liver, and tumor characteristics (n = 667).

![](pone.0181878.t002){#pone.0181878.t002g}

                                                                              TSH, N (%)                                   
  ----------------------------------------------------------------- --------- ------------ ---------- ---------- --------- --
  **Sex**                                                           Male      547          36 (72)    458 (84)   53 (77)   
  Female                                                            120       14 (28)      90 (16)    16 (23)    0.062     
  **Age**                                                           ≤65       339          16 (32)    281 (51)   42 (61)   
  \>65                                                              328       34 (68)      267 (49)   27 (39)    0.007     
  **Diabetes**                                                      NIDDM     152          9 (18)     124 (23)   19 (28)   
  IDDM                                                              78        4 (8)        69 (13)    5 (7)                
  None                                                              437       37 (74)      355 (65)   45 (65)    0.418     
  **BMI (kg/m**^**2**^**)**[^1^](#t002fn003){ref-type="table-fn"}   \<18.5    6            1 (2)      5 (1)      0 (0)     
  18.5--25                                                          229       20 (40)      189 (36)   20 (29)              
  \>25                                                              409       29 (58)      332 (63)   48 (71)    0.470     
  **Etiology**                                                      Alcohol   304          25 (50)    254 (46)   25 (36)   
  HCV                                                               194       10 (20)      156 (29)   28 (41)              
  HBV                                                               52        4 (8)        46 (8)     2 (3)                
  NASH                                                              20        0 (0)        19 (4)     1 (1)                
  Other                                                             97        11 (22)      73 (13)    13 (19)    0.083     
  **Thyroid hormone substitution**                                  Yes       41           12 (24)    20 (4)     9 (13)    
  No                                                                626       38 (76)      528 (96)   60 (87)    \<0.001   
  **Child-Pugh**                                                    A         286          21 (42)    244 (45)   21 (30)   
  B                                                                 219       15 (30)      178 (33)   26 (38)              
  C                                                                 162       14 (28)      126 (23)   22 (32)    0.216     
  **MELD**                                                          \<12      361          27 (54)    302 (55)   32 (46)   
  ≥12                                                               306       23 (46)      246 (45)   37 (54)    0.390     
  **Largest tumor**                                                 ≤5cm      313          34 (68)    252 (46)   27 (39)   
  \>5cm                                                             354       16 (32)      296 (54)   42 (61)    0.005     
  **Macrovascular invasion**                                        No        489          41 (82)    403 (74)   45 (65)   
  Yes                                                               178       9 (18)       145 (27)   24 (35)    0.119     
  **Extrahepatic metastases**                                       No        577          44 (88)    470 (86)   63 (91)   
  Yes                                                               90        6 (12)       78 (14)    6 (9)      0.425     
  **CRP (mg/dl)**[^2^](#t002fn004){ref-type="table-fn"}             \<1       285          22 (48)    239 (46)   24 (36)   
  ≥1                                                                346       24 (52)      279 (54)   43 (64)    0.260     
  **AFP (IU/ml)**[^3^](#t002fn005){ref-type="table-fn"}             ≤100      362          23 (47)    305 (57)   34 (49)   
  \>100                                                             296       26 (53)      235 (44)   35 (51)    0.262     

**Abbreviations**: AFP, α-fetoprotein; BMI, body mass index; CRP, C-reactive protein; HBV, hepatitis B virus; HCV, hepatitis C virus; MELD, model of end-stage liver disease; NASH, non-alcoholic steatohepatitis; (N)IDDM, (non) insulin dependent diabetes mellitus; TSH, thyroid-stimulating hormone.

**Definitions**: TSH low, \<0.44uU/ml; TSH normal, 0.44--3.77uU/ml; TSH high, \>3.77uU/ml

^**1**^ missing, n = 23;

^**2**^ missing, n = 36;

^**3**^ missing, n = 9

Free T~4~ (fT~4~) levels were available in 313 patients. Since sample size of hypothyroid patients (fT~4~ levels below 0.76ng/dl) was too small (n = 4) to allow for robust analysis, fT~4~ levels were divided into two groups (≤1.66 and \>1.66ng/dl, hereafter referred to as 'normal' and 'elevated', respectively). The proportion of female patients was higher in patients with elevated fT~4~ levels (normal vs. elevated fT~4~, 16 vs. 36%; p = 0.025). Thyroid hormone substitution was more frequently observed in patients with elevated fT~4~ (normal vs. elevated fT~4~, 6 vs. 32%; p\<0.001). Finally, subjects with elevated fT~4~ were more likely to have elevated CRP levels (normal vs. elevated fT~4~, 51 vs. 88%; p = 0.001). No association was observed between other variables representing liver function and tumor burden, respectively ([S3 Table](#pone.0181878.s003){ref-type="supplementary-material"}).

Since information on T~3~, T~4~, and fT~3~ was missing in 82--97% of patients due to the retrospective character of this analysis ([S1 Table](#pone.0181878.s001){ref-type="supplementary-material"}), we could not assess their association with patient, liver, and tumor characteristics.

Uni- and multivariate analyses of prognostic factors {#sec013}
----------------------------------------------------

Median survival of the study population (n = 667) was 9.3 months (95%CI, 7.6--11.0 months).

In univariate analysis ([Table 3](#pone.0181878.t003){ref-type="table"}), both, TSH (TSH≤1.7 vs. \>1.7uU/ml, median OS (95%CI), 12.3 (8.9--15.7 months) vs. 7.3 months (5.4--9.2 months); p = 0.003; [Fig 2A](#pone.0181878.g002){ref-type="fig"}) and fT~4~ (fT~4~≤1.66 vs. \>1.66ng/dl, median OS (95%CI), 10.6 (7.5--13.6 months) vs. 3.3 months (2.2--4.3 months); p = 0.007; [Fig 2B](#pone.0181878.g002){ref-type="fig"}) were associated with OS. Patients with manifest hyperthyroid status (n = 17) had worse survival compared to those with normal fT4 levels (i.e., euthyreosis, subclinical hyperthyreosis). The cause of death in patients with hyperthyreosis was tumor progression in 6 patients, liver failure/decompensation in 4 subjects, and unknown in 7 patients. However, thyroid status was not significantly associated with OS, most likely due to small patient numbers in some subgroups.

10.1371/journal.pone.0181878.t003

###### Univariate analysis of prognostic factors (N = 667).

![](pone.0181878.t003){#pone.0181878.t003g}

                                                                                         Overall survival (months)   P-value      
  ----------------------------------------------------------------- ------------- ------ --------------------------- ------------ --
  **Age**                                                           ≤65           339    7.5                         4.9--10.1    
  \>65                                                              328           10.5   8.1--12.9                   0.203        
  **Etiology**                                                      Viral         246    10.5                        7.7--13.3    
  Others                                                            421           8.8    6.7--10.9                   0.326        
  **Child-Pugh**                                                    A             286    16.2                        13.8--18.7   
  B                                                                 219           7.9    5.1--10.8                                
  C                                                                 162           2.4    1.9--2.9                    \<0.001      
  **Largest tumor**                                                 ≤5cm          313    14.3                        11.7--16.9   
  \>5cm                                                             354           6.1    5.0--7.2                    \<0.001      
  **ECOG PS**                                                       0             328    16.7                        14.2--19.3   
  ≥1                                                                339           4.0    3.3--4.8                    \<0.001      
  **Macrovascular invasion**                                        No            489    12.6                        10.7--14.5   
  Yes                                                               178           3.7    2.4--5.0                    \<0.001      
  **Extrahepatic spread**                                           No            577    11.3                        9.3--13.4    
  Yes                                                               90            3.4    1.9--5.0                    \<0.001      
  **First-line therapy**                                            PEI/RFA       138    20.9                        16.6--25.2   
  TACE                                                              180           15.5   13.3--17.7                               
  Sorafenib                                                         63            8.1    4.0--12.2                                
  BSC                                                               152           1.9    1.4--2.4                                 
  Other                                                             134           6.0    4.4--7.6                    \<0.001      
  **AFP (IU/ml)**[^1^](#t003fn002){ref-type="table-fn"}             ≤100          362    14.0                        11.8--16.2   
  \>100                                                             296           5.8    4.5--7.1                    \<0.001      
  **CRP (mg/dl)**[^2^](#t003fn003){ref-type="table-fn"}             \<1           285    17.9                        14.8--20.9   
  ≥1                                                                346           4.1    3.3--4.9                    \<0.001      
  **TSH (uU/ml)**                                                   ≤1.7          336    12.3                        8.9--15.7    
  \>1.7                                                             331           7.3    5.4--9.2                    0.003        
  **fT**~**4**~ **(ng/dl)**[^3^](#t003fn004){ref-type="table-fn"}   ≤1.66         288    10.6                        7.5--13.6    
  \>1.66                                                            25            3.3    2.2--4.3                    0.007        
  **Thyroid hormone substitution**                                  Yes           41     11.9                        4.0--19.7    
  No                                                                626           9.0    7.2--10.7                   0.474        
  **Thyroid status**                                                Euthyreosis   200    10.8                        6.5--15.2    
  Hyperthyreosis                                                    17            3.3    1.4--5.1                                 
  Subclinical hyperthyreosis                                        22            14.7   1.4--28.0                                
  Subclinical hypothyreosis                                         47            6.1    0--13.5                                  
  Hypothyreosis                                                     3             0.7    0.2--1.2                                 
  TH substitution                                                   41            11.9   4.0--19.7                   0.195        

**Abbreviations**: AFP, α-fetoprotein; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT~4~, free tetraiodthyronine; MELD, model of end-stage liver disease; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; TH, thyroid hormone; TSH, thyroid-stimulating hormone.

^**1**^ missing, n = 9;

^**2**^ missing, n = 36;

^3^ missing, n = 354

![Kaplan-Meier survival curves.\
Overall survival (OS) according to (A) thyroid-stimulating hormone (TSH) levels (TSH≤1.7 vs. \>1.7uU/ml, median OS (95%CI), 12.3 (8.9--15.7 months) vs. 7.3 months (5.4--9.2 months); p = 0.003), and (B) free tetraiodthyronine (fT4) levels (fT~4~≤1.66 vs. \>1.66ng/dl, median OS (95%CI), 10.6 (7.5--13.6 months) vs. 3.3 months (2.2--4.3 months); p = 0.007).](pone.0181878.g002){#pone.0181878.g002}

Other variables that were significantly associated with OS included Child-Pugh class, tumor size, Eastern Cooperative Oncology Group (ECOG) performance status (PS), macrovascular invasion (MVI), extrahepatic metastases, first-line therapy, α-fetoprotein (AFP) level, and C-reactive protein (CRP) level. Importantly, thyroid hormone substitution had no impact on OS.

Given that fT~4~ levels were only available in 313 patients, we did not include both TSH and fT~4~ in the same multivariate Cox regression model, but analyzed them separately with all other variables that were significantly associated with OS in univariate analysis. Finally, fT~4~ (HR (95%CI) for fT~4~\>1.66ng/dl, 2.1 (1.3--3.3); p = 0.002) remained an independent prognostic factor for OS ([Table 4](#pone.0181878.t004){ref-type="table"}), while TSH was not significantly associated with OS in multivariate analysis ([S4 Table](#pone.0181878.s004){ref-type="supplementary-material"}).

10.1371/journal.pone.0181878.t004

###### Multivariate analysis of prognostic factors.

![](pone.0181878.t004){#pone.0181878.t004g}

                                         Overall survival   P-value   
  ---------------------------- --------- ------------------ --------- --
  **Child-Pugh**               A         1                            
  B                            1.7       1.3--2.4           0.001     
  C                            2.3       1.5--3.6           \<0.001   
  **Largest tumor**            ≤5cm      1                            
  \>5cm                        1.4       1.1--1.8           0.017     
  **ECOG PS**                  0         1                            
  ≥1                           1.3       0.9--1.8           0.134     
  **Macrovascular invasion**   No        1                            
  Yes                          1.2       0.9--1.7           0.285     
  **Extrahepatic spread**      No        1                            
  Yes                          1.7       1.1--2.5           0.013     
  **First-line therapy**       PEI/RFA   1                            
  TACE                         1.2       0.8--1.8           0.315     
  Sorafenib                    1.4       0.6--2.9           0.409     
  BSC                          6.0       3.8--9.4           \<0.001   
  Other                        1.7       1.2--2.4           0.004     
  **AFP (IU/ml)**              ≤100      1                            
  \>100                        1.5       1.2--2.0           0.003     
  **CRP (mg/dl)**              \<1       1                            
  ≥1                           1.6       1.2--2.2           0.003     
  **fT**~**4**~ **(ng/dl)**    ≤1.66     1                            
  \>1.66                       2.1       1.3--3.3           0.002     

**Abbreviations**: AFP, α-fetoprotein; BSC, best supportive care; CRP, C-reactive protein; ECOG PS, Eastern Cooperative Oncology Group performance status; fT~4~, free tetraiodthyronine; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; TACE, transarterial chemoembolization.

After separating patients into early-intermediate (BCLC A-B) and advanced-terminal (BCLC C-D) stage, fT~4~ remained associated with OS. Median survival in the early-intermediate stage group was 25.3 months (95%CI, 20.1--30.6 months) for fT~4~ ≤1.66 (n = 97) and 15.5 months (95%CI, 9.2--21.8 months) for fT~4~ \>1.66 (n = 8) (p = 0.043). Similarly, in the advanced-terminal stage group, patients with fT~4~ ≤1.66 (n = 191) had a significantly (p = 0.038) longer survival of 4.5 months (95%CI, 3.1--5.8 months) compared to 2.8 months (95%CI, 1.5--4.1 months) in patients with fT~4~ \>1.66 (n = 17).

Discussion {#sec014}
==========

In our cohort, 10% of patients had elevated TSH levels similar to the prevalence of hypothyroidism in patients with HCC reported by Hassan et al. (HCC patients vs. controls, 11.7 vs. 8%) \[[@pone.0181878.ref012]\]. Hypothyroidism has profound effects on metabolism and has therefore been linked to various conditions which either directly constitute an HCC risk factor or have the ability to contribute to the development of known predisposing conditions for HCC, such as obesity \[[@pone.0181878.ref018]--[@pone.0181878.ref021]\], diabetes \[[@pone.0181878.ref022]--[@pone.0181878.ref025]\], non-alcoholic fatty liver disease (NAFLD) \[[@pone.0181878.ref020], [@pone.0181878.ref026], [@pone.0181878.ref027]\], and hepatitis C infection \[[@pone.0181878.ref012], [@pone.0181878.ref028], [@pone.0181878.ref029]\]. Interestingly, Tarantino and colleagues reported that BMI predicted the presence of spleno-renal shunts and spleno-renal shunts were associated with an increased HCC incidence \[[@pone.0181878.ref030]\].

However, in our study, high serum TSH concentration was neither associated with type II diabetes mellitus nor BMI. Although etiology of liver disease was not significantly associated with TSH levels, HCV was more frequently observed in patients with high TSH levels (41%) compared to those with normal (29%) or low (20%) TSH. In contrast, Reddy and colleagues \[[@pone.0181878.ref031]\] found that hypothyroidism was more prevalent in patients with unknown etiology than in those with HCV or alcoholic liver disease. Additionally, we observed NASH only in patients with normal or elevated TSH but not in those with low TSH levels.

Notably, elevated TSH was associated with larger tumors in our study. In contrast, in breast cancer, hypothyroid patients were more likely to be diagnosed with a smaller tumor and at an earlier stage compared to euthyroid patients \[[@pone.0181878.ref032]\]. Moreover, in prostate cancer, serum T~3~ was higher in more advanced clinical stage, even though none of the men had levels above the normal range \[[@pone.0181878.ref033]\].

In terms of survival, patients with higher TSH levels showed a significantly worse outcome in univariate analysis. However, this effect did not hold true upon multivariate analysis when adjusting for other prognostic factors including Child-Pugh class, tumor size, performance status, macrovascular invasion, extrahepatic spread, tumor treatment, AFP, and CRP levels.

Next, we investigated the prevalence of abnormal fT~4~ levels, available in 313 of 667 patients. Elevated fT~4~ was found in 25 patients (4% of all patients, n = 667; 8% of those whose fT~4~ levels where available, n = 313). In comparison, a large study conducted in the United States reported a prevalence of only 0.5% for clinical hyperthyroidism. Notably, they used total instead of free T~4~ concentrations but adjusted for the common T~4~-confounders pregnancy and estrogen therapy \[[@pone.0181878.ref034]\]. In an epidemiologic study by Hassan et al., the prevalence of hyperthyroidism was 1.9% among HCC patients and 1.3% among controls \[[@pone.0181878.ref012]\].

In our cohort, elevated fT~4~ concentrations were not associated with etiology of liver disease and variables representing liver function or tumor burden. However, patients with elevated fT~4~ more frequently had elevated CRP levels which indicate worse prognosis in HCC and could be a reflection of the "inflammatory field effect" \[[@pone.0181878.ref035]\]. This effect could directly fuel tumor progression as CRP levels are an accepted surrogate marker for the release of Interleukin (IL) -6, an important regulator of CRP secretion, which in turn is associated with both acceleration of HCC development and metastasis \[[@pone.0181878.ref035]--[@pone.0181878.ref038]\]. Additionally, thyroid hormone replacement was more common in patients with increased fT~4~ levels (fT~4~≤1.66 vs. \>1.66, 6 vs. 32%).

We next investigated the impact of fT~4~ on the prognosis of HCC patients and found that elevated fT~4~ levels at the time of HCC diagnosis were significantly associated with poor OS. This effect held true even after adjusting for other known prognostic factors for HCC in a multivariate Cox regression model.

These results are supported by several preclinical studies showing that thyroid hormone signaling promotes tumor invasiveness and metastasis \[[@pone.0181878.ref002], [@pone.0181878.ref013], [@pone.0181878.ref015], [@pone.0181878.ref039], [@pone.0181878.ref040]\], and could be of clinical relevance mainly for two reasons. First, fT~4~ is a valuable prognostic parameter in HCC that is widely available, non-invasively collectable, and objective. Second, considering both the association between thyroid hormone substitution and elevated fT~4~ levels as well as the strong prognostic relevance of elevated fT~4~, our data could suggest some caution when replacing thyroid hormones in patients with established HCC, as hormone replacement-induced fT~4~ elevation might render tumors more aggressive. This should especially be considered in patients with advanced HCC receiving sorafenib therapy where hypothyroidism often occurs \[[@pone.0181878.ref041]--[@pone.0181878.ref043]\], and might prompt physicians to initiate hormone replacement therapy.

Notably, other studies reported that T~3~ treatment led to regression of preneoplastic lesions in rodent models of heptocarcinogenesis \[[@pone.0181878.ref044], [@pone.0181878.ref045]\].

The main limitation of this study was the lack of patients with low fT~4~ levels, which precluded the investigation of effects of overt hypothyroidism on HCC and only allowed analyzing the effect of hypothyroidism using TSH levels. This especially impeded the analysis of the impact of thyroid hormones on HCC with metabolic background. Furthermore, the small sample size of patients with abnormal fT~4~ levels did not allow subgroup analyses within the BCLC stages and Child-Pugh class. As thyroid hormones may exert opposing effects at different stages of HCC development and progression some effects could evade detection when analysis is performed without differentiation according to tumor stage \[[@pone.0181878.ref002]\]. However, after grouping patients into early-intermediate (BCLC A-B) and advanced-terminal stage (BCLC C-D), the negative impact of elevated fT~4~ on survival remained significant in both subgroups. Additionally, non-thyroidal illness syndrome (NTIS), characterized by low serum T~3~ with normal T~4~ levels, is associated with HCC and other malignancies \[[@pone.0181878.ref046], [@pone.0181878.ref047]\]. The fact that T~3~ and fT~3~ levels were missing in most of our patients represents another potential bias we could not address in our analysis. In light of the stated limitations, this study could not adequately investigate the hypothesis of a dual role of thyroid hormones in HCC \[[@pone.0181878.ref002]\].

In conclusion, high TSH level was associated with larger tumor size but not with survival when adjusted for known prognostic factors for HCC. Elevation of fT~4~ resulted in poor survival and remained an independent prognostic factor for OS. These results can be considered as hypothesis-generating paving the path for further work. Prospective studies including clinically hypothyroid patients and subgroup analyses of all tumor stages are needed to further elucidate the role of thyroid hormones in HCC.
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